OUR PIPELINE
Advancing the next generation of antibody therapeutics
Enabled by our VAST platform, we are building a portfolio of differentiated antibody programs to carve new opportunities in therapeutics and biodefense.
Oncology
Discovery
Lead Selection
IND Enabling
Phase 1
Partner
MUC-1
Discovery
Lead
IND
Phase 1
Partner:—
MUC-4
Discovery
Lead
IND
Phase 1
Partner:—
GPCR
Discovery
Lead
IND
Phase 1
Partner:—
Others
Discovery
Lead Selection
IND Enabling
Phase 1
Partner
Fentanyl
Discovery
Lead
IND
Phase 1
Partner:Licensed to Hepione Therapeutics
Carfentanil
Discovery
Lead
IND
Phase 1
Partner:Licensed to Hepione Therapeutics
INVESTMENTS AND PARTNERSHIPS
Let's build the future of antibody innovation together
We are actively seeking investors to support our mission of developing novel antibodies into life-changing therapeutics.
Panosome is also eager to explore licensing, co-development, and other strategic partnership opportunities to maximize the impact of our technology and pipeline.